Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estramustine, Docetaxel, and Carboplatin in Hormone Refractory Prostate Cancer
NCT00005810Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2000
- Primary completion
- Dec 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of estramustine, docetaxel and carboplatin in prostate cancer (PCa), sponsored by Cancer and Leukemia Group B. Primary endpoints: Objective and PSA Response Rate up to 2 years and Duration of Response up to 2 years. Started Mar 2000; status: completed.
02
Drugs
estramustinedocetaxelcarboplatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00005810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005810.